# PERSEVERE: genomically directed post-neoadjuvant residual TNBC

Source: https://onco.cc/trials/nct04849364/  
OnCo record `nct04849364` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study assigned extra treatment after surgery using blood and tumour tests. It stopped and is no longer an access route.

## Summary

Registry status terminated, last updated 2025-05-31. Enrollment is 52 actual. Residual early TNBC after neoadjuvant therapy and definitive resection. The ctDNA-enriched, genomically directed platform included talazoparib/capecitabine and inavolisib/capecitabine strategies, with pembrolizumab rules differing by assigned arm. The registry states termination for a funder decision; that administrative reason is not an efficacy result.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-10
- Registry id: NCT04849364
- Phase: 2
- Setting: Residual early TNBC after neoadjuvant therapy and definitive resection
- Sponsor: Bryan Schneider, MD
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT04849364: https://clinicaltrials.gov/study/NCT04849364

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Inavolisib](https://onco.cc/drugs/inavolisib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Talazoparib](https://onco.cc/drugs/talazoparib/)

---
JSON: https://onco.cc/api/v1/entities/nct04849364.json